Drilon, Alexander

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine

Sarcoma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 2,824

Entrectinib in Patients with Advanced or Metastatic NTRK Fusion-Positive Solid Tumours: Integrated Analysis of Three Phase 1-2 Trials

Doebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., et al. (2020) · The Lancet Oncology

Lung Cancer Treatments and MutationsSarcoma Diagnosis and Treatment

Cited by 1,790

Larotrectinib in Patients with TRK Fusion-Positive Solid Tumours: A Pooled Analysis of Three Phase 1/2 Clinical Trials

Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., van Tilburg, C. M., Nagasubramanian, R., Berlin, J. D., Federman, N., et al. (2020) · The Lancet Oncology

Sarcoma Diagnosis and TreatmentLung Cancer Treatments and Mutations

Cited by 1,028

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., et al. (2018) · Nature

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 780

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

Jordan, E. J., Kim, H. R., Arcila, M. E., Barron, D., Chakravarty, D., Gao, J., Chang, M. T., Ni, A., Kundra, R., Jonsson, P., et al. (2017) · Cancer Discovery

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 643

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

Drilon, A., Ou, S.-H. I., Cho, B. C., Kim, D.-W., Lee, J., Lin, J. J., Zhu, V. W., Ahn, M.-J., Camidge, D. R., Nguyen, J., et al. (2018) · Cancer Discovery

Lung Cancer Treatments and MutationsCancer Mechanisms and Therapy

Cited by 504

Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches

Drilon, A., Wang, L., Arcila, M. E., Balasubramanian, S., Greenbowe, J. R., Ross, J. S., Stephens, P., Lipson, D., Miller, V. A., Kris, M. G., et al. (2015) · Clinical Cancer Research

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 274

Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

Drilon, A., Camidge, D. R., Lin, J. J., Kim, S.-W., Solomon, B. J., Dziadziuszko, R., Besse, B., Goto, K., de Langen, A. J., Wolf, J., et al. (2024) · New England Journal of Medicine

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 240

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion–Positive Lung Cancer

Lin, J. J., Choudhury, N. J., Yoda, S., Zhu, V. W., Johnson, T. W., Sakhtemani, R., Dagogo-Jack, I., Digumarthy, S. R., Lee, C., Do, A., et al. (2021) · Clinical Cancer Research

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 145

KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures

Friedlaender, A., Drilon, A., Weiss, G. J., Banna, G. L., & Addeo, A. (2020) · Cancer Treatment Reviews

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 118

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

Drilon, A., Chiu, C.-H., Fan, Y., Cho, B. C., Lu, S., Ahn, M.-J., Krebs, M. G., Liu, S. V., John, T., Otterson, G. A., et al. (2022) · JTO Clinical and Research Reports

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 113

Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas

Eng, J., Woo, K. M., Sima, C. S., Plodkowski, A., Hellmann, M. D., Chaft, J. E., Kris, M. G., Arcila, M. E., Ladanyi, M., & Drilon, A. (2015) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 107

RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non–Small Cell Lung Carcinomas Sensitive to MEK Inhibition

Hayashi, T., Desmeules, P., Smith, R. S., Drilon, A., Somwar, R., & Ladanyi, M. (2018) · Clinical Cancer Research

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 90

NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations

Drilon, A., Horan, J. C., Tangpeerachaikul, A., Besse, B., Ou, S.-H. I., Gadgeel, S. M., Camidge, D. R., van der Wekken, A. J., Nguyen-Phuong, L., Acker, A., et al. (2023) · Cancer Discovery

Lung Cancer Treatments and MutationsCancer Mechanisms and Therapy

Cited by 52

The NCI-MATCH: A National, Collaborative Precision Oncology Trial for Diverse Tumor Histologies

Murciano-Goroff, Y. R., Drilon, A., & Stadler, Z. K. (2021) · Cancer Cell

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 33

Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers

Drilon, A., Schoenfeld, A. J., Arbour, K. C., Litvak, A., Ni, A., Montecalvo, J., Yu, H. A., Panora, E., Ahn, L., Kennedy, M., et al. (2019) · Molecular Case Studies

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 31

Clinical and Morphologic Characteristics of Extracellular Signal-Regulated Kinase Inhibitor-Associated Retinopathy

Francis, J. H., Canestraro, J., Haggag-Lindgren, D., Harding, J. J., Diamond, E. L., Drilon, A., Li, B. T., Iyer, G., Schram, A. M., & Abramson, D. H. (2021) · Ophthalmology Retina

Drug-Induced Ocular ToxicityRetinal Diseases and Treatments

Cited by 15

Local therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors

Yu, H. A., Sima, C. S., Drilon, A. E. D. C., Varghese, A. M., Pietanza, M. C., Azzoli, C. G., Rizvi, N. A., Krug, L. M., Kris, M. G., Miller, V. A., et al. (2012) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 10